US OK’s AZ’ Farxiga for heart failure with reduced ejection fraction
Farxiga is the first sodium glucose co-transporter 2 inhibitor cleared by the FDA to treat heart failure with reduced ejection fraction
Read More
Tag: HFrEF
Novartis announces positive results from two Entresto trials
Heart failure is a chronic and progressive condition, which impacts 26 million people worldwide.
Read More
Positive results continue success for Forxiga
Forxiga has had a string of successes recently, as it was recommended by NICE and had its EU marketing authorisation updated earlier this month.
Read More
Timely use of Novartis’ Entresto could save thousands of lives
Timely and broad adoption of Novartis’ Entresto by all eligible heart failure patients with reduced ejection fraction (HFrEF) could prevent or postpone more than 28,000 deaths each year in the US alone, finds a new analysis published in JAMA Cardiology.
Read More
Global guidelines back Novartis’ heart drug Entresto
Novartis’ ‘breakthrough’ therapy Entresto has received a strong endorsement in updated EU and US guidelines on the treatment of heart failure.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
